Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease
Several oncogenic mechanisms have been identified for MET, including MET amplification, fusions, mutations in the tyrosine kinase domain and exon 14 skipping alterations. MET exon 14 mutations are found in about 3-5% of non-small-cell lung cancers. Dysregulation of the MET receptor leads to cell pro...
Saved in:
Main Authors: | Juan Bautista Blaquier (Author), Gonzalo Recondo (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non-small cell lung cancer patients in resource constrained community hospitals
by: Anurag Mehta, et al.
Published: (2021) -
MET Exon 14 Variants in Non-Small Cell Lung Carcinoma: Prevalence, Clinicopathologic and Molecular Features
by: Lisi Yuan, et al.
Published: (2023) -
Exon Skipping in a Dysf-Missense Mutant Mouse Model
by: Jakub Malcher, et al.
Published: (2018) -
Natural Exon Skipping Sets the Stage for Exon Skipping as Therapy for Dystrophic Epidermolysis Bullosa
by: Jeroen Bremer, et al.
Published: (2019) -
First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
by: Alessandro Inno, et al.
Published: (2023)